Terms: = Head and neck cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1623 results:
1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
2. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
3. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract] [Full Text] [Related]
4. Advances in the Imaging of Esophageal and Gastroesophageal Junction Malignancies.
Ruby L; Jayaprakasam VS; Fernandes MC; Paroder V
Hematol Oncol Clin North Am; 2024 Jun; 38(3):711-730. PubMed ID: 38575457
[TBL] [Abstract] [Full Text] [Related]
5. Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
Ch'ng ES
Breast Cancer; 2024 May; 31(3):496-506. PubMed ID: 38546966
[TBL] [Abstract] [Full Text] [Related]
6. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
7. Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.
Guglielmi G; Del Re M; Gol LS; Bengala C; Danesi R; Fogli S
Eur J Pharmacol; 2024 Apr; 969():176424. PubMed ID: 38402929
[TBL] [Abstract] [Full Text] [Related]
8. Salivary gland carcinoma: Towards a more personalised approach.
Rached L; Saleh K; Casiraghi O; Even C
Cancer Treat Rev; 2024 Mar; 124():102697. PubMed ID: 38401478
[TBL] [Abstract] [Full Text] [Related]
9. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and her2 positive metastatic salivary duct carcinoma. A case report.
Čavka L; Zakotnik B
J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
[TBL] [Abstract] [Full Text] [Related]
10. Epigenomic analyses identify FOXM1 as a key regulator of anti-tumor immune response in esophageal adenocarcinoma.
Ziman B; Yang Q; Zheng Y; Sheth M; Nam C; Zhao H; Zhang L; Hu B; Bhowmick NA; Sinha UK; Lin DC
Cell Death Dis; 2024 Feb; 15(2):152. PubMed ID: 38373993
[TBL] [Abstract] [Full Text] [Related]
11. Dual anti-her2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC.
Song PN; Lynch SE; DeMellier CT; Mansur A; Gallegos CA; Wright BD; Hartman YE; Minton LE; Lapi SE; Warram JM; Sorace AG
Sci Rep; 2024 Feb; 14(1):3771. PubMed ID: 38355949
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with her2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract] [Full Text] [Related]
13. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Wainberg ZA; Kang YK; Lee KW; Qin S; Yamaguchi K; Kim IH; Saeed A; Oh SC; Li J; Turk HM; Teixeira A; Hitre E; Udrea AA; Cardellino GG; Sanchez RG; Zahlten-Kümeli A; Taylor K; Enzinger PC
Gastric Cancer; 2024 May; 27(3):558-570. PubMed ID: 38308771
[TBL] [Abstract] [Full Text] [Related]
14. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
15. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.
Porschen R; Fischbach W; Gockel I; Hollerbach S; Hölscher A; Jansen PL; Miehlke S; Pech O; Stahl M; Vanhoefer U; Ebert MPA
United European Gastroenterol J; 2024 Apr; 12(3):399-411. PubMed ID: 38284661
[TBL] [Abstract] [Full Text] [Related]
16. Thyroid Ultrasound Image Database and Marker Mask Inpainting Method for Research and Development.
Li X; Fu C; Xu S; Sham CW
Ultrasound Med Biol; 2024 Apr; 50(4):509-519. PubMed ID: 38267314
[TBL] [Abstract] [Full Text] [Related]
17. Survival analysis of palliative radiotherapy in patients with her-2+ metastatic breast cancer.
Li X; Zhong X; Xu H; Wang J; Liu X; Wang Y; He L; Ma J; Li G; Liu L
Front Endocrinol (Lausanne); 2023; 14():1305429. PubMed ID: 38260126
[TBL] [Abstract] [Full Text] [Related]
18. Genomics and tumor microenvironment of breast mucoepidermoid carcinoma based on whole-exome and RNA sequencing.
Ge Y; Lin X; He J; Chen W; Lin D; Zheng Y; Yang L; Xu F; Li Z
Diagn Pathol; 2024 Jan; 19(1):15. PubMed ID: 38243319
[TBL] [Abstract] [Full Text] [Related]
19. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for her2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Tokunaga M; Machida N; Mizusawa J; Ito S; Yabusaki H; Hirao M; Watanabe M; Imamura H; Kinoshita T; Yasuda T; Hihara J; Fukuda H; Yoshikawa T; Boku N; Terashima M
Gastric Cancer; 2024 May; 27(3):580-589. PubMed ID: 38243037
[TBL] [Abstract] [Full Text] [Related]
20. Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells.
Horpratraporn K; Adchariyasakulchai P; Sainamthip P; Ketchart W
Med Oncol; 2024 Jan; 41(2):58. PubMed ID: 38231469
[TBL] [Abstract] [Full Text] [Related]
[Next]
